Kiniksa Pharmaceuticals Ltd. (KNSA): Citigroup sees 78% price potential and outlines criteria for preferred biotechs!
Reading Time: 3 minutes
Kiniksa Pharmaceuticals Ltd. (KNSA) is a biotechnology company specializing in severe diseases. The focus is on cardiovascular diseases and inflammation. Kiniksa's main drug is ARCALYST, which is used for the treatment of recurrent pericarditis – a recurring inflammation of the heart's outer lining that causes severe chest pain. The company is also working on new drugs like KPL-387. This is a potential successor to ARCALYST that could be administered as a monthly injection. KPL-1161 is another anti-inflammatory drug that would need to be injected...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
